Zafgen (ZFGN) Stock Expected to Languish Until More is Known - Cowen
Tweet Send to a Friend
Cowen analyst Phil Nadeau weighed in Zafgen (NASDAQ: ZFGN) announced that a death occurred in its ongoing double-blind, placebo controlled ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
